3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
11
Lung Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Rectal Neoplasms
4
Colorectal Neoplasms
4
Colonic Neoplasms
4
Carcinoma, Ovarian Epithelial
4
Carcinoma, Intraductal, Noninfiltrating
4
Breast Carcinoma In Situ
4
Brain Neoplasms
4
Unspecified Adult Solid Tumor, Protocol Specific
3
Squamous Cell Carcinoma of Head and Neck
3
Prostatic Neoplasms
3
Ovarian Neoplasms
3
Liver Neoplasms
3
Head and Neck Neoplasms
3
Carcinoma, Hepatocellular
3
Salivary Gland Neoplasms
2
Precancerous Conditions
2
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Gliosarcoma
2
Glioblastoma
2
Esophageal Neoplasms
2
Central Nervous System Neoplasms
2
Carcinoma, Renal Cell
2
Adenocarcinoma Of Esophagus
2
Waldenstrom Macroglobulinemia
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Interventions
Etoposide
79
Carboplatin
67
Cisplatin
58
durvalumab
30
Irinotecan
29
Radiotherapy
27
atezolizumab
23
Topotecan
21
anlotinib
19
Nivolumab
15
Drug Therapy
15
Radiosurgery
14
Paclitaxel
13
Gemcitabine
13
apatinib
12
toripalimab
10
Platinum
10
Docetaxel
10
tislelizumab
9
Temozolomide
9
PM 01183
9
pembrolizumab
7
olaparib
7
Magnetic Resonance Spectroscopy
7
Ipilimumab
7
Bevacizumab
7
Albumin-Bound Paclitaxel
7
irinotecan sucrosofate
6
Counseling
6
sintilimab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Small Cell Lung Carcinoma
×
Mass Spectrometry
×
Clear all
NCT00900094
2012-02-07
IRB 2000-294
University of Michigan Rogel Cancer Center
Completed
200 enrolled